Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TRK 950 (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Doxorubicin liposomal; Fluorouracil; Fluorouracil; Folinic acid; Gemcitabine; Imiquimod; Ipilimumab; Irinotecan; Nivolumab; Paclitaxel; Pembrolizumab; Ramucirumab
  • Indications Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Toray Industries

Most Recent Events

  • 09 Apr 2025 Planned End Date changed from 1 Mar 2025 to 1 Jun 2026.
  • 09 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jun 2026.
  • 09 Apr 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top